Generated by AI
Helus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for mental health conditions, with a particular emphasis on serotonergic compounds and psychedelic-based medicines. The company’s current pipeline centers on proprietary novel serotonergic agonists designed to act on serotonin pathways and support neuroplasticity, including candidates under development for depression and anxiety disorders. Helus Pharma Inc. works across preclinical and clinical research, advancing programs through studies aimed at psychiatric and neurological applications. The company serves the biotechnology and pharmaceutical sectors, where it contributes to the broader effort to expand treatment options for patients with unmet mental health needs. Headquartered in Toronto, Canada, Helus Pharma Inc. is positioned as a research-driven developer of innovative neuropsychiatric therapeutics.
Website100 King Street West
Toronto, ON, M5X 1C9
Canada
The latest articles about CYBN.
The latest insider stock transactions for Cybin Inc. (HELP.NE).
Summary of Jun 5's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company’s annual and special meeting of shareholders held on Se
Summary of Apr 28's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about CYBN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.